Accelerate Diagnostics (NASDAQ:AXDX) Raised to “Hold” at StockNews.com

Accelerate Diagnostics (NASDAQ:AXDX) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Monday.

Accelerate Diagnostics Stock Up 0.6 %

Shares of AXDX stock opened at $1.65 on Monday. Accelerate Diagnostics has a 52-week low of $0.73 and a 52-week high of $5.23. The stock has a market cap of $41.32 million, a PE ratio of -0.57 and a beta of 0.59. The business has a 50-day simple moving average of $1.79 and a 200-day simple moving average of $1.51.

Institutional Investors Weigh In On Accelerate Diagnostics

An institutional investor recently bought a new position in Accelerate Diagnostics stock. Y Intercept Hong Kong Ltd purchased a new stake in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 19,866 shares of the medical research company’s stock, valued at approximately $34,000. Y Intercept Hong Kong Ltd owned approximately 0.08% of Accelerate Diagnostics as of its most recent SEC filing. 17.14% of the stock is currently owned by institutional investors.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.